David Lindqvist
David Lindqvist writes about appetite, body weight, glucose control, and related metabolic research. He dissects randomized trials and observational cohorts, paying attention to what participants ate, how long the study ran, and which outcome was primary. He keeps his conclusions limited to the data and often notes when a finding comes from a single small study. His tone is understated and methodical.
Posts
Studies5 min read
Retatrutide's 80-week trial shows weight loss and knee pain relief
In an 80-week trial, retatrutide led to weight loss up to 25% and reduced knee osteoarthritis pain more than placebo. A second diabetes trial used the same design.
Studies5 min read
Tirzepatide users stay on treatment longer than semaglutide users
Three real-world studies looked at [tirzepatide](/peptides/tirzepatide) in routine care. They found higher adherence than semaglutide, Zepbound had the most super responders, and lithium monitoring matters.
Studies4 min read
What the studies show about AOD-9604 in 2026
AOD-9604 is a lab-made growth hormone fragment. In 2026, animal studies still show fat loss without insulin effects, but human research stopped at early safety reports.
Studies4 min read
Liraglutide lowered blood pressure and kidney markers in meta-analyses
Three new reviews looked at liraglutide in diabetic kidney disease, polyendocrine metabolic ovarian syndrome (PMOS), a hormonal condition formerly called PCOS, and skin reactions. The clearest finding was a 5.00 mmHg drop in systolic blood pressure in people with diabetic kidney disease.
Studies5 min read
Semaglutide studies show kidney and heart changes beyond weight loss
Three new studies looked beyond the scale at semaglutide: a human kidney trial, animal heart failure models, and a UK digital weight-loss program. The results add detail on kidney blood flow and scarring, heart and liver remodeling, and the role of weight tracking.
Studies5 min read
Orforglipron 36 mg lowered weight and blood sugar more than 12 mg
A pooled analysis of six trials found that 36 mg of orforglipron produced larger reductions in weight, waist size, and blood sugar than 12 mg, with similar gastrointestinal side effects. A separate Japanese study reported mostly mild side effects over one year.
Studies6 min read
Retatrutide not detected in urine, reports show weight loss and DKA
A urine test designed for anti-doping could not find retatrutide in four people. Separate case reports describe a 58.8% weight loss in Prader-Willi syndrome and diabetic ketoacidosis in type 1 diabetes.
Studies6 min read
Early weight loss predicts six-month liraglutide response
Three new liraglutide reports looked at early weight loss as a predictor, adolescent safety at lower doses, and gut changes in mice. The clearest adult finding is that one-month weight loss tracked six-month response.
Studies6 min read
Semaglutide in sepsis, schizophrenia, and heart failure adds detail
Three recent studies looked at semaglutide in a rat model of heart injury and infection, interviews with people taking antipsychotics, and a review of obesity-related heart failure. They add detail without changing the main clinical findings.